Evidence map›Paper›PMID 37696981›Full record

ArticleGene therapy2023

A pilot study to determine the optimal dose of scAAVIL-1ra in a large animal model of post-traumatic osteoarthritis.

P Thampi, K A Seabaugh, L M Pezzanite, C R Chu, J N Phillips, J C Grieger, C W McIlwraith, R J Samulski, L R Goodrich

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gene therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

P ThampiOrthopaedic Research Center, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, CO, USA.
K A SeabaughOrthopaedic Research Center, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, CO, USA.
L M PezzaniteOrthopaedic Research Center, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, CO, USA.
C R ChuDepartment of Orthopaedic Surgery, Stanford University, Stanford, CA, USA.
J N PhillipsOrthopaedic Research Center, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, CO, USA.
J C GriegerGene Therapy Center, University of North Carolina, Chapel Hill, NC, USA.
C W McIlwraithOrthopaedic Research Center, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, CO, USA.
R J SamulskiGene Therapy Center, University of North Carolina, Chapel Hill, NC, USA.
L R GoodrichOrthopaedic Research Center, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, CO, USA. laurie.goodrich@colostate.edu.ORCID 0000-0002-8010-4429
Colorado State University · USUniversity of North Carolina at Chapel Hill · USVA Palo Alto Health Care System · US

Funding

U.S. Department of Defense (United States Department of Defense) 62326995-156499U.S. Department of Defense (United States Department of Defense) W81XWH1810572
6 · The paper itself

Abstract

Gene therapy approaches using adeno-associated viral vectors have been successfully tested in the equine post-traumatic osteoarthritis (PTOA) model. Owing to differences in the levels of transgene expression and adverse tissue reactions observed in published studies, we sought to identify a safe therapeutic dose of scAAVIL-1ra in an inflamed and injured joint that would result in improved functional outcomes without any adverse events. scAAVIL-1ra was delivered intra-articularly over a 100-fold range, and horses were evaluated throughout and at the end of the 10-week study. A dose-related increase in IL-1ra levels with a decrease in PGE

Indexed as

Interleukin 1 Receptor Antagonist ProteinOsteoarthritisAnimalsGenetic VectorsHorsesModels, AnimalPilot ProjectsInterleukin 1 Receptor Antagonist Protein

Identifiers

PMID37696981
PMCPMC10727982
OpenAlexW4386615818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.